Skip to main content
. 2020 Jan 29;2(1):fcaa006. doi: 10.1093/braincomms/fcaa006

Table 1.

Overview of included patients, demographics and clinical outcome

Pt ID Gender Group GALT_1/GALT_2 GALT activity, % IQ Tremor/ TRS Dystonia/ DRS POI BMD Z-score ≤ −2 SD
1 M Non-screened p.Gln188Arg/400delT <3.3 NA No
2 F Non-screened

p.Gln188Arg/p.Lys285Asn

p.Lus285Asn

<3.3 77 No
3 M Non-screened p.Gln188Arg/p.Ser135Trp <3.3 >85 NA
4 M Non-screened −/− <3.3 NA
5 F Non-screened p.Ser135Trp/p.Arg51Gln <3.3 78 Yes Yes
6 M Non-screened p.Gln188Arg/p.Gln188Arg <3.3 Yes/7 No/− NA
7 F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 78 Yes No
8 F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 Yes/− No/− Yes No
9 M Non-screened p.Gln188Arg/p.Lys127Glu <3.3 70 NA
10 M Non-screened p.Gln188Arg/p.Gln188Arg <3.3 74 NA No
11 M Non-screened p.Gln188Arg/p.Gln188Arg <3.3 45 Yes/38 Yes/6 NA No
12d F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 81 Yes/4 No/0 Yes No
13 M Non-screened c.329-2A>C/c.329-2A>C <3.3 Yes/− No/− NA Yes
14 F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 83 Yes No
15 F Non-screened p.Gln188Arg/p.Ser135Trp <3.3 57 Yes No
16 F Non-screened p.Gln188Arg/p.Gln188Arg 53 No/4 No/0 Yes No
17 F Non-screened c.329-2A>C/c.329-2A>C <3.3 No/− No/− Yes No
18 F Non-screened p.Ser135Leu/p.Ser135Leu <3.3 71 No/1 No/0 No
19 F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 82 No/0 No/0 ? No
20c F Non-screened p.Gln188Arg/p.Leu195Pro <3.3 88 Yes/5 No/0 Yes No
21 F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 71 ? No
22 M Non-screened p.Gln188Arg/p.Gln188Arg 91 NA No
23 M Non-screened p.Gln188Arg/p.Lys195Pro <3.3 93 No/0 No/0 NA No
24 M Non-screened p.Gln188Arg/p.Ser135Trp <3.3 98 No/0 No/0 NA No
25 F Non-screened p.Arg205*/p.Trp316* <3.3 97 No Yes
26a M Non-screened p.Gln188Arg/p.Lys285Asn <3.3 76 Yes/7 No/0 NA No
27a M Non-screened p.Gln188Arg/p.Lys285Asn <3.3 86 Yes/6 No/0 NA No
28 F Non-screened p.Ser135Leu/p.Ser135Leu 3.9 61 No/0 No/0 No No
29 M Non-screened p.Gln188Arg/p.Ser135Trp 3.9 65 Yes/6 No/0 NA No
30e M Non-screened p.Gln188Arg/c.377 + 7A>C <3.3 87 No/3 No/0 NA No
31 M Non-screened p.Gln188Arg/p.Lys285Asn <3.3 49 Yes/29 Yes/4 NA No
32 M Non-screened p.Gln188Arg/p.Leu195Pro <3.3 103 Yes/8 No/0 NA No
33b F Non-screened p.Arg148Gln/p.Trp316* <3.3 88 Yes/13 No/0 ? No
34 F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 46 Yes/− No/− No
35f F Screened, FS p.Gln188Arg/p.Gln188Arg <3.3 77 Yes/4 No/0 Yes No
36 M Screened, FS p.Gln188Arg/p.Lys127Glu <3.3 61 NA No
37 F Screened, FS p.Gln188Arg/p.Arg148Gln <3.3 No
38f F Screened, FS p.Gln188Arg/p.Gln188Arg <3.3 71 Yes No
39d F Screened, FS p.Gln188Arg/p.Gln188Arg <3.3 61 Yes/34 Yes/1 Yes Yes
40c F Screened, FS p.Gln188Arg/p.Leu195Pro <3.3 52 Yes/10 Yes/2 ?
41e* M Screened, FS p.Gln188Arg/c.377 + 7A>C <3.3 95 NA Yes
42b* M Screened, FS p.Arg148Gln/p.Trp316* <3.3 68 Yes/− No/− NA No
43* F Screened, NBS p.Gln188Arg/p.Leu195Pro <3.3 82 No/− No/−
44* F Screened, NBS p.Gln188Arg/p.Gln188Arg <3.3 64 No/− No/−
45* M Screened, NBS p.Gln188Arg/p.Gln188Arg <3.3 89 No/− No/− NA
46* M Screened, NBS p.Gln188Arg/p.Gln188Arg <3.3 64 No/− No/− NA
47* F Screened, NBS p.Gln188Arg/p.Gln188Arg <3.3 70 No/− No/−
48* M Screened, NBS p.Ser135Leu/p.*380Argext*50 <3.3 95 No/− No/− NA
49* F Screened, NBS p.Gln188Arg/p.Gln188Arg <3.3 83
50g* F Variant p.Val128lle/p.Val128lle 8.7 86 No/− No/−
51g* F Variant p.Val128lle/p.Val128lle 8.7 89 No/− No/−
52* M Variant p.Gln188Arg/p.Met219Lys 7.2 96 No/− No/− NA
53* F Variant p.Gln188Arg/c.1-96T>G 3.6 86 No/− No/−
54g* M Variant p.Val128lle/p.Val128lle 9.3 91 No/− No/− NA
55* M Variant p.Arg201His/p.Arg201His 8.9 NA
56g* F Variant p.Val128lle/p.Val128lle 6.3

*Age <12 years.

Pt ID: patient ID; F: female; M: male; FS: family screening; IQ: intelligence quotient; TRS: tremor rating scale; DRS: dystonia rating scale; BMD: bone mineral density; NA: not applicable; -: data not available; ?: data unclear; a, b, c, d, e, f: sibs, patients are ordered by group and listed by decreasing age; grey shades: age <12 years; bold: patients diagnosed late.